These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2388477)

  • 1. Correlation of the proliferative index of residual leukemia with outcome in patients treated with sequential high dose ara-C and asparaginase.
    Powell BL; Kute TE; Craig JB; Lyerly ES; Gregory BW; Do KA; Contento MM; Capizzi RL
    Leukemia; 1990 May; 4(5):316-20. PubMed ID: 2388477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia--a Cancer and Leukemia Group B Study.
    Capizzi RL; Davis R; Powell B; Cuttner J; Ellison RR; Cooper MR; Dillman R; Major WB; Dupre E; McIntyre OR
    J Clin Oncol; 1988 Mar; 6(3):499-508. PubMed ID: 3162515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia.
    Jahns-Streubel G; Reuter C; Unterhalt M; Schleyer E; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1995 Nov; 9(11):1857-63. PubMed ID: 7475275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia.
    Capizzi RL; White C
    Yale J Biol Med; 1988; 61(1):11-22. PubMed ID: 3163212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
    Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response.
    Burke PJ; Karp JE; Vaughan WP
    J Natl Cancer Inst; 1981 Sep; 67(3):529-38. PubMed ID: 6944525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
    Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
    Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation versus cytoreduction during remission induction in acute nonlymphoblastic leukemia treated with sequential high-dose ara-C and asparaginase.
    Ross DW; Capizzi RL
    Cancer; 1984 Apr; 53(8):1651-4. PubMed ID: 6697302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of the resistance to Ara-C blast cells in acute myeloid leukemia using flow cytometry].
    Lacombe F; Belloc F; Dumain P; Puntous M; Cony-Makhoul P; Bernard P; Boisseau MR; Reiffers J
    Bull Cancer; 1995; 82(5):349-56. PubMed ID: 7626842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status of therapy and prognosis in acute adult leukemia].
    Gmür J
    Ther Umsch; 1996 Feb; 53(2):111-6. PubMed ID: 8629260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
    Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
    Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E; Koc Y; Kars A; Alakavuklar M; Tekuzman G; Firat D
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract]   [Full Text] [Related]  

  • 19. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
    Archimbaud E; Fenaux P; Reiffers J; Cordonnier C; Leblond V; Travade P; Troussard X; Tilly H; Auzanneau G; Marie JP
    Leukemia; 1993 Mar; 7(3):372-7. PubMed ID: 8445942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.